N4 Pharma PLC Cash Flow-to-Debt Ratio
N4 Pharma PLC cash flow-to-debt ratio. N4 Pharma PLC (N4P) has a Cash Flow-to-Debt Ratio of -5.67x as of June 2025, meaning its operating cash flow of GBX-444.37K could theoretically repay -6% of its total liabilities (GBX78.37K) in one year. Check N4P cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of N4 Pharma PLC (1991–2024)
Cash flow-to-debt ratio of N4 Pharma PLC from 1991 to 2024. Historical debt coverage capacity for N4 Pharma PLC across 34 annual periods. Check N4P total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
N4 Pharma PLC Cash Flow-to-Debt Ratio by Year (1991–2024)
N4 Pharma PLC cash flow-to-debt ratio by year from 1991 to 2024. Year-by-year debt coverage analysis for N4 Pharma PLC. For the full cash flow conversion analysis, see N4P cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -7.81x | GBX-971.50K | GBX124.37K | ▲ +47.2% |
| 2023 | -14.79x | GBX-1.21 Million | GBX81.73K | ▼ -39.1% |
| 2022 | -10.63x | GBX-828.26K | GBX77.89K | ▼ -27.6% |
| 2021 | -8.33x | GBX-1.77 Million | GBX212.73K | ▼ -2.1% |
| 2020 | -8.16x | GBX-1.38 Million | GBX169.08K | ▲ +21.4% |
| 2019 | -10.38x | GBX-806.00K | GBX77.68K | ▼ -46.7% |
| 2018 | -7.07x | GBX-1.34 Million | GBX190.12K | ▼ -33.3% |
| 2017 | -5.31x | GBX-950.80K | GBX179.22K | ▼ -8.6% |
| 2016 | -4.88x | GBX-376.00K | GBX77.00K | ▲ +90.4% |
| 2015 | -50.71x | GBX-862.00K | GBX17.00K | ▼ -11935.2% |
| 2014 | -0.42x | GBX-340.00K | GBX807.00K | ▼ -336.8% |
| 2013 | -0.10x | GBX-87.00K | GBX902.00K | ▲ +63.0% |
| 2012 | -0.26x | GBX-324.00K | GBX1.24 Million | ▼ -138.4% |
| 2011 | 0.68x | GBX996.00K | GBX1.47 Million | ▲ +182.7% |
| 2010 | 0.24x | GBX249.00K | GBX1.04 Million | ▼ -63.1% |
| 2009 | 0.65x | GBX755.00K | GBX1.16 Million | ▲ +296.0% |
| 2008 | -0.33x | GBX-184.00K | GBX554.00K | ▼ -210.0% |
| 2007 | 0.30x | GBX160.00K | GBX530.00K | ▲ +329.3% |
| 2006 | -0.13x | GBX-67.00K | GBX509.00K | ▼ -350.7% |
| 2005 | -0.03x | GBX-113.00K | GBX3.87 Million | ▼ -184.9% |
| 2004 | 0.03x | GBX140.00K | GBX4.07 Million | ▲ +90.9% |
| 2003 | 0.02x | GBX85.00K | GBX4.71 Million | ▲ +111.8% |
| 2002 | -0.15x | GBX-739.00K | GBX4.85 Million | ▼ -477.7% |
| 2001 | 0.04x | GBX210.00K | GBX5.21 Million | ▲ +185.2% |
| 2000 | -0.05x | GBX-380.00K | GBX8.03 Million | ▼ -141.6% |
| 1999 | -0.02x | GBX-171.00K | GBX8.73 Million | ▲ +92.7% |
| 1998 | -0.27x | GBX-2.72 Million | GBX10.10 Million | ▼ -165.5% |
| 1997 | -0.10x | GBX-2.66 Million | GBX26.17 Million | ▼ -218.5% |
| 1996 | 0.09x | GBX2.02 Million | GBX23.55 Million | ▲ +1225.3% |
| 1995 | 0.01x | GBX163.00K | GBX25.21 Million | ▼ -96.3% |
| 1994 | 0.18x | GBX3.34 Million | GBX18.88 Million | ▲ +591.9% |
| 1993 | 0.03x | GBX310.00K | GBX12.14 Million | ▼ -82.9% |
| 1992 | 0.15x | GBX2.72 Million | GBX18.22 Million | ▲ +223.7% |
| 1991 | -0.12x | GBX-2.42 Million | GBX20.05 Million | — |